
USD
$0.00
(0.00%
)At Close (As of Nov 14, 2025)
$6.76M
Market Cap
-
P/E Ratio
-17.1
EPS
$46.53
52 Week High
$1.76
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $3.4M |
| Total Revenue | $9.4M |
| Cost Of Revenue | $6M |
| Costof Goods And Services Sold | $6M |
| Operating Income | -$9M |
| Selling General And Administrative | $9.9M |
| Research And Development | $1.8M |
| Operating Expenses | $12M |
| Investment Income Net | - |
| Net Interest Income | -$75K |
| Interest Income | $18K |
| Interest Expense | $92K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $606K |
| Income Before Tax | -$9M |
| Income Tax Expense | $12K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$8.9M |
| Ebitda | -$8.3M |
| Net Income | -$9M |
| Field | Value (USD) |
|---|---|
| Total Assets | $6.5M |
| Total Current Assets | $2.7M |
| Cash And Cash Equivalents At Carrying Value | $1.1M |
| Cash And Short Term Investments | $1.1M |
| Inventory | $28K |
| Current Net Receivables | $1.1M |
| Total Non Current Assets | $3.8M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $775K |
| Intangible Assets Excluding Goodwill | $775K |
| Goodwill | $1.4M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $423K |
| Other Non Current Assets | - |
| Total Liabilities | $3.9M |
| Total Current Liabilities | $3.1M |
| Current Accounts Payable | $987K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $694K |
| Total Non Current Liabilities | $807K |
| Capital Lease Obligations | $1.3M |
| Long Term Debt | $20K |
| Current Long Term Debt | $172K |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $1.5M |
| Other Current Liabilities | $1.4M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $2.6M |
| Treasury Stock | - |
| Retained Earnings | -$54M |
| Common Stock | $107K |
| Common Stock Shares Outstanding | $404K |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$7.3M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $606K |
| Capital Expenditures | $79K |
| Change In Receivables | - |
| Change In Inventory | -$9.1K |
| Profit Loss | - |
| Cashflow From Investment | -$79K |
| Cashflow From Financing | $5.6M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$9M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $3.4M |
| Total Revenue | $9.4M |
| Cost Of Revenue | $6M |
| Costof Goods And Services Sold | $6M |
| Operating Income | -$9M |
| Selling General And Administrative | $9.9M |
| Research And Development | $1.8M |
| Operating Expenses | $12M |
| Investment Income Net | - |
| Net Interest Income | -$75K |
| Interest Income | $18K |
| Interest Expense | $92K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $606K |
| Income Before Tax | -$9M |
| Income Tax Expense | $12K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$8.9M |
| Ebitda | -$8.3M |
| Net Income | -$9M |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
bioAffinity Technologies, Inc. (BIAF) is a pioneering biotechnology company headquartered in San Antonio, Texas, dedicated to revolutionizing cancer diagnostics and treatment. Leveraging its proprietary non-invasive technologies, the firm focuses on enhancing early detection and targeted therapies to improve patient outcomes in oncology. With a strong commitment to innovation and research, bioAffinity is well-positioned to address significant challenges in cancer care, aiming to make meaningful contributions to the field and improve the lives of patients.